RESUMO
AIMS/HYPOTHESIS: This study estimated the economic efficiency (1) of intensive blood glucose control and tight blood pressure control in patients with type 2 diabetes who also had hypertension, and (2) of metformin therapy in type 2 diabetic patients who were overweight. METHODS: We conducted cost-utility analysis based on patient-level data from a randomised clinical controlled trial involving 4,209 patients with newly diagnosed type 2 diabetes conducted in 23 hospital-based clinics in England, Scotland and Northern Ireland as part of the UK Prospective Diabetes Study (UKPDS). Three different policies were evaluated: intensive blood glucose control with sulphonylurea/insulin; intensive blood glucose control with metformin for overweight patients; and tight blood pressure control of hypertensive patients. Incremental cost : effectiveness ratios were calculated based on the net cost of healthcare resources associated with these policies and on effectiveness in terms of quality-adjusted life years gained, estimated over a lifetime from within-trial effects using the UKPDS Outcomes Model. RESULTS: The incremental cost per quality-adjusted life years gained (in year 2004 UK prices) for intensive blood glucose control was 6,028 UK pounds, and for blood pressure control was 369 UK pounds. Metformin therapy was cost-saving and increased quality-adjusted life expectancy. CONCLUSIONS/INTERPRETATION: Each of the three policies evaluated has a lower cost per quality-adjusted life year gained than that of many other accepted uses of healthcare resources. The results provide an economic rationale for ensuring that care of patients with type 2 diabetes corresponds at least to the levels of these interventions.
Assuntos
Pressão Sanguínea/fisiologia , Diabetes Mellitus Tipo 2/economia , Diabetes Mellitus Tipo 2/fisiopatologia , Hipoglicemiantes/economia , Adulto , Idoso , Anti-Hipertensivos/economia , Anti-Hipertensivos/uso terapêutico , Glicemia/metabolismo , Análise Custo-Benefício , Custos e Análise de Custo , Complicações do Diabetes/economia , Complicações do Diabetes/epidemiologia , Diabetes Mellitus Tipo 2/sangue , Humanos , Hipertensão/prevenção & controle , Hipoglicemiantes/uso terapêutico , Pessoa de Meia-Idade , Reino UnidoRESUMO
This article examines the likely effect of the 30% private health insurance rebate on private health insurance coverage. It is based on a survey of the Australia population conducted in April-May 1999 which collected information on health insurance purchasing behaviour and intentions. These data are used to predict the subsidy's likely effect on hospital insurance coverage, with estimates ranging from 30.5% to 34.3% by May 2000. Ancillary insurance membership is forecast to increase to between 32.7% and 37.2% of the population over the same period. The 30% insurance rebate will probably produce, at best, a small increase in hospital insurance membership. The cost of the rebate is estimated at $1.4 billion in 1999-2000. Given the small increases in projected membership, the cost of the initiative is very high.
Assuntos
Comportamento do Consumidor/estatística & dados numéricos , Honorários e Preços/tendências , Financiamento Pessoal/estatística & dados numéricos , Pesquisas sobre Atenção à Saúde , Cobertura do Seguro/estatística & dados numéricos , Seguro de Hospitalização/economia , Seguro de Serviços Médicos/economia , Fatores Etários , Austrália , Comportamento de Escolha , Comportamento do Consumidor/economia , Humanos , Renda , Cobertura do Seguro/tendências , Seguro de Hospitalização/estatística & dados numéricos , Seguro de Serviços Médicos/estatística & dados numéricos , Setor Privado/economia , Distribuição AleatóriaRESUMO
This study describes the methodology and presents preliminary results of an economic appraisal of a program to use mobile mammographic screening units in rural areas of Australia. The benefits of the project are measured using the travel cost method. Since mammograms are a 'binary good', conventional welfare analysis must be modified and discrete choice models used to estimate the demand for screening. The results suggest that the level of welfare benefits depends on the distance a town is from the nearest fixed screening unit. In the 10 towns studied, the economic benefits of mobile screening outweighed the economic costs if a rural town is situated 29 km or more from a fixed mammographic screening unit.
Assuntos
Acessibilidade aos Serviços de Saúde/economia , Mamografia/economia , Unidades Móveis de Saúde/economia , Aceitação pelo Paciente de Cuidados de Saúde/psicologia , Serviços de Saúde Rural/economia , Viagem/economia , Idoso , Neoplasias da Mama/diagnóstico , Área Programática de Saúde , Comportamento de Escolha , Análise Custo-Benefício , Feminino , Humanos , Mamografia/estatística & dados numéricos , Pessoa de Meia-Idade , Unidades Móveis de Saúde/estatística & dados numéricos , Modelos Estatísticos , New South Wales , Aceitação pelo Paciente de Cuidados de Saúde/estatística & dados numéricos , Avaliação de Programas e Projetos de Saúde , Serviços de Saúde Rural/estatística & dados numéricosRESUMO
Nasometry is an objective technique that was originally devised for assessing nasality of speech. It is based on a comparison of the acoustic output from the nose and the mouth for a given spoken word or phrase. Subjects with nasal obstruction tend to have "hyponasal" speech and this study compares the standard technique of active anterior rhinomanometry with nasometry in the objective assessment of nasal obstruction. There was a significant association between the Total Nasal Resistance (TNR) and the nasality measurements using nasophonemically enhanced test phrases in 15 adult subjects. This test has obvious advantages over rhinomanometry which can be difficult, time consuming and unreliable particularly in the younger and severely congested patient.